Epidermal growth factor reduces resistance to doxorubicin.
Epidermal growth factor (EGF) increased the sensitivity to doxorubicin (DOX) of a human squamous carcinoma cell line, A431. The relative enhancement of sensitivity by EGF was greater in 2 DOX-resistant sublines, A431/A5 and A431/A10, established by growing cells from surviving colonies after treatment of A431 cells with DOX. A greater number of EGF receptors (both high- and low-affinity binding sites) was found for resistant A431/A5 and A431/A10 cells than for parental cells. The enhanced drug responsiveness is not directly related to EGF effects on growth, as growth inhibition by EGF appears to be similar among the 3 sublines.
Kwok
T T
TT
Laboratory of Cell and Molecular Biology, SRI International, Menlo Park, CA 94025.
Sutherland
R M
RM
D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage*; D004351:Drug Resistance; D004357:Drug Synergism; D004815:Epidermal Growth Factor / Q000008:administration & dosage* / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000378:metabolism
D004815:Epidermal Growth Factor; D004317:Doxorubicin; D066246:ErbB Receptors